Subclinical Hypothyroidism Is Associated with Increased Risk for Cancer Mortality in Adult Taiwanese—A 10 Years Population-Based Cohort

Fen-Yu Tseng1,8, Wen-Yuan Lin3,5,6, Chia-Ing Li4,5, Tsai-Chung Li4,7,9, Cheng-Chieh Lin3,5,6,9, Kuo-Chin Huang2,6

1 Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, 2 Family Medicine, National Taiwan University Hospital, Taipei, Taiwan, 3 Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan, 4 Medical Research, China Medical University Hospital, Taichung, Taiwan, 5 School of Medicine, China Medical University, Taichung, Taiwan, 6 Graduate Institute of Clinical Medicine Science, China Medical University, Taichung, Taiwan, 7 Graduate Institute of Biostatistics, China Medical University, Taichung, Taiwan, 8 Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan, 9 Institute of Health Care Administration, College of Health Science, Asia University, Taichung, Taiwan

* bretthuang@ntu.edu.tw

Abstract

Background

The association between subclinical hypothyroidism (SCH) and cancer mortality is seldom discussed.

Methods

A total of 115,746 participants without thyroid disease history, aged 20 and above, were recruited from four nationwide health screening centers in Taiwan from 1998 to 1999. SCH was defined as a serum thyroid-stimulating hormone (TSH) level of 5.0–19.96 mIU/L with normal total thyroxine concentrations. Euthyroidism was defined as a serum TSH level of 0.47–4.9 mIU/L. Cox proportional hazards regression analyses were used to estimate the relative risks (RRs) of death from cancer for adults with SCH during a 10-year follow-up period.

Results

Among 115,746 adults, 1,841 had SCH (1.6%) and 113,905 (98.4%) had euthyroidism. There were 1,532 cancer deaths during the 1,034,082 person-years follow-up period. Adjusted for age, gender, body mass index, diabetes, hypertension, dyslipidemia, smoking, alcohol drinking, betel nut chewing, physical activity, income, and education level, the RRs (95% confidence interval) of cancer deaths among subjects with SCH versus euthyroid subjects were 1.51 (1.06 to 2.15). Cancer site analysis revealed a significant increased risk of bone, skin and breast cancer among SCH subjects (RR 2.79, (1.01, 7.70)). The risks of total
cancer deaths were more prominent in the aged (RR 1.71, (1.02 to 2.87)), in females (RR 1.69 (1.08 to 2.65)), and in heavy smokers (RR 2.24, (1.19 to 4.21)).

**Conclusions**

Subjects with SCH had a significantly increased risk for cancer mortality among adult Taiwanese. This is the first report to demonstrate the association between SCH and cancer mortality.

**Introduction**

The association between thyroid hormone and tumorigenesis has been discussed for more than 30 years. In *in vitro* studies, it was reported that triiodothyronine (T3) facilitated chemical carcinogenesis [1]. Removal of T3 or T4 from serum eliminated X-ray induced neoplastic transformation, while adding T3 re-established the expected frequency of transformation [2]. Theoretically, deficit or excess of thyroid hormone may alter the hormonal milieu thus initiate or promote tumor growth. However, no consensus has been reached concerning the effects of different thyroid function status on cancer incidence or mortality.

Subclinical hypothyroidism (SCH) is defined as normal serum thyroxine (T4) level with elevated thyroid stimulating hormone (TSH). The proposed adverse consequences of SCH include systemic hypothyroid symptoms, psychiatric symptoms, progression to overt hypothyroidism, and hypercholesterolemia [3–4]. Effects of SCH on cardiovascular events, all-cause mortality, and cardiovascular death have been discussed repeatedly in literature [5–11]. However, only a few reports discuss the associations between SCH and cancer mortality. Our previous study reported increased risk for all-cause and cardiovascular disease (CVD) mortality in adults with SCH [9]. In this study, we aimed to evaluate the impact of SCH on cancer mortality in a large Taiwanese cohort.

**Patients and Methods**

**Subjects and measurements**

The data were collected from four private nationwide MJ Health Screening Centers in Taiwan. The registered health practitioners in these centers provide a multidisciplinary team approach of health assessment for their members. Most of the members undergo health examinations every 3–4 years voluntarily and approximately 30% of them will receive the same health check-up every year. All the 124,456 participants who received a health exam at MJ centers during the period between 1998 and 1999, aged 20 years and above, were recruited into this study. Nine hundred fifty-three participants (0.8%) who had a history of thyroid disease with medication treatment and 3,310 participants (2.6%) with missing TSH or total T4 level at entry were excluded. SCH was defined as a serum TSH level of 5.0–19.96 mIU/L with normal total T4 concentrations (57.9–154.4 nmol/L). Euthyroidism was defined as a serum TSH level of 0.47–4.9 μIU/mL [9]. Therefore, participants with serum TSH level ≥ 20 mIU/L or < 0.47 mIU/L were also excluded (n = 4,447). Finally, 115,746 participants were included for analyses in the study as in our previous study [9].

The age and gender distribution of our study was similar to the Taiwan national population [12]. Deaths were ascertained by computer linkage to the national death registry (death certificates created by the Department of Health, Taiwan) using ID numbers. All deaths that occurred...
between study entry (year 1998) and December 2008 were included. Deaths with the International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) codes 140 to 208 were classified as cancer deaths, while individual site-specific cancers were further classified by the ICD-9-CM codes.

**Anthropometric index and laboratory assays**

The anthropometric characteristics, blood pressure (BP), plasma glucose, total cholesterol (TCHOL), high-density lipoprotein cholesterol (HDL-C), and triglycerides were measured as described in the previous report [13]. Thyroid function (TSH and Total T4) was also measured (ABBOTT AxSYM, Illinois, U.S.A.). The coefficients of variation were 3.6%~4.3% at level 2.837~3.419 mIU/L and 8.1%~8.8% at level 15.32~19.727 mIU/L for the precision of TSH assay, and were 2.8%~3.6% at level 7.9~8.5μg/dL for that of total T4. In brief, trained staff measured height (measured to nearest 0.1cm) and weight (measured to nearest 0.1kg). Body mass index (BMI) was calculated as weight (kg) divided by height squared (m²). All anthropometric measurements were performed twice, and the mean value was used for analysis. The BP was measured in the right arm using an appropriately-sized cuff and a standard mercury sphygmomanometer while participants were in a seated position. Blood was drawn with minimal trauma from an antecubital vein in the morning after a 12-hour overnight fast. Diabetes was defined as a fasting glucose ≥ 126 mg/dL and/or history of diabetes and taking oral hypoglycemic agents or insulin. Hypertension was defined as systolic BP ≥ 140 mmHg, and/or diastolic BP ≥ 90 mmHg, and/or history of hypertension or taking anti-hypertensive drugs. Dyslipidemia was defined as TCHOL ≥ 200mg/dL and/or triglycerides ≥ 150 mg/dL and/or HDL-C < 40 mg/dL in men and <50 mg/dL in women and/or history of dyslipidemia and taking anti-dyslipidemia drugs. Ethic approval for patient recruitment and data analyses was obtained from the MJ Research Foundation Review Committee in Taiwan. Written informed consents have been obtained from all the 124,456 participants.

**Questionnaire**

Cigarette smoking, alcohol intake, betel nut chewing, and physical activity histories were recorded for each subject using questionnaires as in previous reports [14–15]. Current, former, or never users for smoking, alcohol intake, and betel nut chewing were defined as those who reported the current use, any prior use, or never use of these substances, respectively, at baseline survey. The cumulative exposure to smoking was assessed by recording the duration (years) and quantity (number of cigarettes/day). Former users were also asked for their age at quitting. Cumulative pack-years of smoking were calculated as smoking-years multiplied by average daily cigarette use divided by 20. Cumulative pack-years for smokers were categorized into two groups (Low: <10 pack-years; High: ≥ 10 pack-years), so smoking status was categorized as none (0 pack-years), low (0~9.9 pack-years), and high (≥ 10 pack-years). Physical activity was classified into three levels: none to mild (exercise less than one hour per week), moderate (exercise one to four hours per week), and vigorous (exercise more than five hours per week) physical activity. Income status was sub-divided into three levels: low (< USD 12,500/year), middle (12,500~37,500/year), and high (≥37,500/year). Education was also sub-divided into three levels: low (elementary school and below), middle (junior and senior high school), and high (college/university and above).

**Statistical analysis**

The data were presented as the means and standard deviation for continuous variables. Student’s t test for unpaired data was used for the comparison of mean values between two groups.
Proportions and categorical variables were tested by the $\chi^2$ test. The unadjusted Kaplan-Meier survival curves of cancer mortality for SCH and euthyroid subjects are shown in Fig 1. Cox proportional hazards regression analyses adjusted for potential confounders were used to estimate the relative risks (RRs) for cancer mortality [16–17]. We adjusted the covariates according to the cancer risk factors, or on the basis of their relationship with either SCH (predictor) or cancer death (outcome) in univariate analysis ($p < 0.05$). For example, age and gender are strongly associated with mortality, so we adjusted these two covariates in our Cox proportional hazards regression analyses. Lifestyle and socioeconomic status such as physical activity, income level, and education level are risk factors for mortality, so we adjusted these covariates. Smoking, alcohol drinking, betel nut chewing, diabetes, hypertension, obesity, and dyslipidemia are associated with increased risk of cancer and/or cancer mortality, so we also adjusted these covariates. The RRs were calculated and presented with 95% confidence interval (CI). Participants with missing covariate data were excluded in the Cox proportional hazards regression analyses. Competing risk approached by cumulative incidence competing risk estimate...
were analyzed. Site-specific cancer deaths among subjects with SCH or euthyroidism were compared. We performed stratified analysis by gender, age, TSH level, or smoking status at entry for the association between SCH and risk of cancer death. All analyses were performed using the PC version of SPSS statistical software (17th version, SPSS Inc., Chicago, IL, USA).

Role of funding source

The funding source had no role in the study design, data collection, data analysis, data interpretation, writing of the report, or in the decision to submit the paper for publication. All authors had full access to all the data in the study and KCH had final responsibility for the decision to submit for publication.

Results

At the baseline survey, there were 1,841 (1.6%) subjects with SCH and 113,905 (98.4%) subjects with euthyroidism. The prevalence of SCH was 0.9% (512/54,983) in men and 2.2% (1,329/60,763) in women, respectively. Subjects with SCH tended to be females (72.2% vs 52.2%), were older (47.1±14.1 vs 42.9±13.9 y/o), and had higher BMI, BP, fasting glucose, TCHOL, HDL-C, and triglycerides levels than subjects with euthyroidism. Those with SCH also differed with euthyroid subjects in smoking, alcohol consumption, betel nut chewing, income, and education (Table 1).

There were 3,669 deaths during the 10 years of follow-up. Among them, 1,532 deaths were due to cancer (38 in SCH subjects and 1494 in euthyroid subjects). The cancer death rate among SCH subjects was significantly higher than that among euthyroid subjects (2.06% vs 1.31%, Chi-Square p = 0.0051). The comparison of cancer mortality in subjects with subclinical hypothyroidism or euthyroidism was shown in Fig 1. The unadjusted Kaplan-Meier survival curves revealed significantly more cancer deaths among subjects with SCH (Log-rank test, p<0.001).

Competing risk approached by cumulative incidence competing risk estimate were done in Table 2. After adjustment for age, gender, BMI, diabetes, hypertension, dyslipidemia, smoking, alcohol drinking, physical activity, income, and education level, the RR of cancer deaths among subjects with SCH versus euthyroid subjects was 1.51 (95% CI, 1.06 to 2.15). To clarify the effects of potential diseases on mortality, we excluded subjects who died during the first 3 years of follow-up. After excluding study subjects who died during the first 3 years of follow-up, compared with subjects with euthyroidism, the adjusted RRs for cancer death for subjects with SCH were 1.61 (95% CI, 1.09 to 2.61) (Table 2).

We further analyzed the difference of cancer deaths between SCH and euthyroid subjects according to the sites of the cancer. Subjects with SCH had significant higher risks of death from bone, skin and breast cancer than euthyroid subjects (RR 2.79, 95% CI 1.01 to 7.70) (Table 3).

There were no significant interactions (P > 0.05) between SCH/euthyroidism groups and age group/gender group/TSH status/smoking status for predicting the risk of cancer mortality. However, gender, age, serum TSH level, and smoking status might be important risk factors for cancer mortality. We therefore stratified these groups and presented the results in Table 4. Compared to subjects with euthyroidism, both male and female subjects with SCH had increased crude RRs of cancer deaths. The adjusted RR of cancer deaths among female SCH subjects persisted as statistically significant (RR 1.69, 95% CI 1.08 to 2.65) than female euthyroid subjects (Table 4). Increasing risks of cancer death was more prominent at aged subjects. In subjects with age equal or older than 65 years, the adjusted RR of cancer death was 1.71 (95% CI 1.02 to 2.87) when compared SCH subjects to euthyroid subjects (Table 4). Subjects with
Table 1. Baseline characteristics of subjects with subclinical hypothyroidism or euthyroidism.

|                      | Subclinical hypothyroidism (n = 1,841) | Euthyroidism (n = 113,905) | P value |
|----------------------|----------------------------------------|---------------------------|---------|
| Age (years)¹         | 47.1±14.1                              | 42.9±13.9                 | <0.001  |
| Male (n, %)²         | 512 (27.8%)                            | 54,471 (47.8%)           | <0.001  |
| BMI (kg/m²)¹         | 23.5±3.7                               | 23.1±3.5                 | <0.001  |
| Systolic BP (mmHg)¹  | 124.2±23.0                             | 120.4±20.6               | <0.001  |
| Diastolic BP (mmHg)¹ | 74.7±12.8                              | 73.4±12.7                | <0.001  |
| Fasting glucose (mmol/L)¹ | 5.62±1.62                           | 5.48±1.29                | <0.001  |
| TCHOL (mmol/L)¹      | 5.36±1.04                              | 5.2±1.00                 | <0.001  |
| Triglycerides (mmol/L)¹ | 1.54±1.13                           | 1.41±1.19                | <0.001  |
| HDL-C (mmol/L)¹      | 1.29±0.41                              | 1.26±0.40                | <0.001  |
| TSH (mIU/L)          | 7.07±2.44                              | 1.56±0.79                | <0.001  |
| T4 (nmol/L)          | 93.1±17.3                              | 99.9±19.1                | <0.001  |
| Diabetes (n, %)²     | 122 (6.6%)                             | 5430 (4.8%)              | <0.001  |
| Hypertension (n, %)² | 516 (28.0%)                            | 22,728 (20.0%)           | <0.001  |
| Smoking (n = 110,386)² |                                    |                          | <0.001  |
| Never                | 1,411 (81.1%)                          | 77,045 (70.9%)           |         |
| Former               | 100 (5.7%)                             | 7,148 (6.6%)             |         |
| Current              | 230 (13.2%)                            | 24,452 (22.5%)           |         |
| Alcohol consumption (n = 106,136)² |                                |                          | <0.001  |
| Never                | 1,360 (82.7%)                          | 82,023 (78.5%)           |         |
| Former               | 60 (3.6%)                              | 3,612 (3.5%)             |         |
| Current              | 225 (13.7%)                            | 18,856 (18.0%)           |         |
| Betel nut chewing (n = 109,332)² |                                |                          | <0.001  |
| Never                | 1,615 (93.8%)                          | 96,312 (89.5%)           |         |
| Former               | 44 (2.6%)                              | 5,380 (5.0%)             |         |
| Current              | 63 (3.7%)                              | 5,918 (5.5%)             |         |
| Physical activity (n = 109,003)²    |                                |                          | 0.252   |
| None/mild            | 872 (50.7%)                            | 53,639 (50.0%)           |         |
| Moderate             | 577 (33.5%)                            | 37,828 (35.3%)           |         |
| Vigorous             | 271 (15.8%)                            | 15,816 (14.7%)           |         |
| Income (n = 108,593)² |                                |                          | <0.001  |
| Low                  | 1,035 (61.6%)                          | 51,278 (48.0%)           |         |
| Middle               | 568 (33.8%)                            | 48,833 (45.7%)           |         |
| High                 | 76 (4.5%)                              | 6,803 (6.4%)             |         |
| Education (n = 112,286)²   |                                |                          | <0.001  |
| Low                  | 634 (35.7%)                            | 25,355 (22.9%)           |         |
| Middle               | 645 (36.3%)                            | 40,270 (36.4%)           |         |
| High                 | 497 (28.5%)                            | 44,885 (40.7%)           |         |

¹Student t-test was used for comparing mean values of continuous variables between groups; data were shown as the mean ± SD; log transformation were used for normal distribution
²Pearson chi-square test was used for categorical data; data were shown as percentage
Abbreviations: BMI, body mass index; BP, blood pressure; TCHOL, total cholesterol; HDL-C, high-density lipoprotein cholesterol; TSH, thyroid-stimulating hormone. T4: thyroxine.

doi:10.1371/journal.pone.0122955.t001
TSH level between 5.0 to 9.99 μIU/mL had significantly higher risks of cancer death than euthyroid subjects (adjusted RR 1.61, 95% CI 1.12 to 2.31) (Table 4). High-dose smokers had higher RRs for cancer mortality than the never smokers or low-dose smokers. The adjusted RR of cancer deaths in SCH subjects versus euthyroid subjects among those with high-dose smokers was 2.24 (95% CI: 1.19 to 4.21) (Table 4).

TSH level between 5.0 to 9.99 μIU/mL had significantly higher risks of cancer death than euthyroid subjects (adjusted RR 1.61, 95% CI 1.12 to 2.31) (Table 4). High-dose smokers had higher RRs for cancer mortality than the never smokers or low-dose smokers. The adjusted RR of cancer deaths in SCH subjects versus euthyroid subjects among those with high-dose smokers was 2.24 (95% CI: 1.19 to 4.21) (Table 4).

Table 2. Relative risks (95% confidence interval) of subclinical hypothyroidism for cancer mortality using Cox proportional hazards regression analyses, unadjusted or adjusted for potential confounders.

| Death (n) | Cancer Mortality Rate Per 1,000 Person-Years | Unadjusted Cancer mortality relative risk (95% confidence interval) | Adjusted<sup>δ</sup> Cancer mortality relative risk (95% confidence interval) |
|----------|-----------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Euthyroidism |                                              |                                                              |                                                              |
| 1998/1999-2008 | 1,494 | 1.468 | 1.00 (reference) | 1.00 (reference) |
| 2001/2002-2008<sup>#</sup> | 1,171 | 1.152 | 1.00 (reference) | 1.00 (reference) |
| SCH |                                              |                                                              |                                                              |
| 1998/1999-2008 | 38 | 2.322 | 1.59 (1.15 to 2.19)<sup>†</sup> | 1.51 (1.06 to 2.15)<sup>⋆</sup> |
| 2001/2002-2008<sup>#</sup> | 31 | 1.899 | 1.77 (1.26 to 2.49)<sup>†</sup> | 1.61 (1.09 to 2.61)<sup>⋆</sup> |

<sup>⋆</sup>p < 0.05;  
<sup>†</sup>p < 0.01;  
<sup>δ</sup>Adjusted RR: adjusted for age, gender, body mass index, diabetes, hypertension, dyslipidemia, smoking, alcohol drinking, betel nut chewing, physical activity status, income, and education level.  
<sup>#</sup>Excluded those who died during first 3 years follow-up (only deaths that occurred after more than 3 years of follow-up were included).

Cancer mortality was determined with a competing risk approach by cumulative incidence competing risk estimate with adjustment for non-cancer mortality. The models used Cox proportional hazards regression analyses adjusted for potential confounders.

doi:10.1371/journal.pone.0122955.t002

Table 3. Site-specific cancer deaths of subjects with SCH or euthyroidism.

| SCH (n) | Euthyroidism (n) | Adjusted relative risk (95% C.I.)<sup>b</sup> |
|----------------|------------------|-----------------------------------------------|
| Total 1,841 | 113,905          |                                               |
| All cancer deaths 38 | 1,494 | 1.51 (1.06, 2.15)<sup>c</sup> |
| Oral cavity (140–149)<sup>a</sup> 2 | 103 | 1.68 (0.41, 6.85) |
| Digestive (150–159)<sup>a</sup> 18 | 696 | 1.64 (1.00, 2.70) |
| Respiratory (160–165)<sup>a</sup> 11 | 333 | 1.81 (0.89, 3.67) |
| Bone, skin, breast (170–176)<sup>a</sup> 4 | 76 | 2.79 (1.01, 7.70)<sup>c</sup> |
| Genitourinary (ICD 179–189)<sup>a</sup> 1 | 133 | 0.34 (0.05, 2.41) |
| Others and unspecified (190–199)<sup>a</sup> 1 | 53 | 1.21 (0.17, 8.84) |
| Hematopoietic (200–208) <sup>a</sup> 1 | 100 | 0.68 (0.10, 4.93) |

SCH: subclinical hypothyroidism  
<sup>a</sup>: subject number  
<sup>b</sup>: confidence interval  
<sup>c</sup>: relative risks of deaths among SCH subjects versus euthyroid subjects  
<sup>c</sup>: adjusted for age, gender, body mass index, diabetes, hypertension, dyslipidemia, smoking, alcohol drinking, betel nut chewing, physical activity status, income, and education level. P < 0.05

doi:10.1371/journal.pone.0122955.t003
Discussion

In literature reviews, the prevalence of SCH was between 4% and 20%, higher in the aged and in women [18–21]. A previous study in Southern Taiwan reported a SCH prevalence of 1.5% in women and 1.7% in men [22]. Comparable to that study, the prevalence of SCH was 0.9% in men, 2.2% in women, and 1.6% in total in this cohort.

The status of BMI, DM, hyperlipidemia, or hypertension in SCH varied in previous literature. BMI has been reported to be positively correlated with serum TSH levels [23–24], but some other studies reported no difference in BMI between subjects with SCH or euthyroid status [25–28]. Thyroid disorders may cause dyslipidemia. It was reported that levels of TCHOL, triglyceride, low-density lipoprotein cholesterol (LDL-C) elevate as thyroid function declines [19, 25, 27–30]. The association between SCH and hypertension was controversial in previous
literature. Some, but not all, studies demonstrated a higher prevalence of hypertension in SCH subjects [25, 31–32]. Previous literature demonstrated no difference in levels of fasting glucose or hemoglobin A1C [27–28], and the prevalence of diabetes mellitus [5, 25–26] between the SCH and euthyroid subjects. Obesity, hypertension, diabetes, and dyslipidemia had been associated with cancer incidence or mortality [33–40]. Smoking, alcohol consumption and betel nut chewing were also known as risk factors for lung, pancreatic, kidney, colorectal, or oropharyngeal cancer, respectively [41–43]. Our analysis revealed that participants with SCH were older, had higher BMI, BP, fasting glucose, TCHOL, triglyceride levels, and higher rates of smoking, alcohol consumption, and betel nut chewing than those with euthyroidism. Our analysis revealed that subjects with SCH had significantly more risk factors for cancer than euthyroid subjects.

The association between hypothyroidism and cancer risk is controversial. Only a few studies discuss the association between SCH and cancer risks. Hellevik et al. reported that hypothyroidism was not associated with cancer risk [44]. It was observed that breast cancer might occur more frequently in hypothyroid women [45], while some researchers reported lower risk, delayed onset, smaller tumor size, or fewer metastases of breast cancer in hypothyroid patients [46–47]. Hoffman et al. reported that use of thyroid supplements does not increase the risk of developing breast cancer [48], while others reported that the risks of cancer increased in patients who received thyroid supplements for hypothyroidism [49–50].

Debates also exist concerning the influence of hypothyroidism and SCH on cancer prognosis. Goldman et al. reported that hypothyroid women had no significant increase in standardized mortality ratio of cancer [51]. Hercebergs et al. reported a case with metastatic lung cancer having no tumor recurrence after a myxedema coma episode [52]. Metso et al. reported that RAI-treated hyperthyroidism increased overall, CVD and cancer mortality, but the development of hypothyroidism reduced mortality significantly [53]. In patients with renal cell carcinoma treated by sunitinib or sorafenib, development of SCH or hypothyroidism was identified as an independent predictor of survival [54–55]. In patients with head and neck tumors, iatrogenic hypothyroidism secondary to regimens for cancers was associated with longer survival [56]. In a literature review, the association between hypothyroidism and cancer prognosis had been discussed in lung cancer, various solid tumors, breast cancer, renal cell carcinoma, anaplastic thyroid cancer, and high-grade gliomas, etc [57]. In our study, compared with euthyroid subjects, the relative risks of cancer deaths in SCH subjects significantly increased, especially in bone, skin, or breast cancer (ICD-9-CM codes 170–176). The effects of SCH on cancer mortality persisted even if we excluded mortality within the first 3 years and after adjustment with demographic, anthropometric, clinical, and socioeconomic characteristics. Our analysis suggests that SCH is an independent risk factor for cancer mortality. This observation was never reported before.

SCH increased cancer mortality in both genders, but the effect of SCH on cancer death was less statistically significant in men. The effects of SCH may vary in different age groups. Our previous study reported a more significantly increased RR of SCH for all-cause and CVD mortality in the aged group [9]. In this study, relative risk of cancer death in subjects with SCH was not significantly increased in the younger age (less than 65 years old) group. Statistically significant increased adjusted relative risk for cancer deaths in SCH subjects was noted in the older age group. A significant association between SCH and all-cause and CVD mortality in subjects with TSH levels ranging from 5 to 9.9 mIU/l had been reported in our previous study [9]. The present study also revealed a significant association between SCH and cancer deaths in subjects with TSH levels ranging from 5 to 9.9 mIU/l. With relatively small numbers, the results became unstable in subjects with higher TSH levels. Our analysis revealed prominent effects of SCH in
cancer deaths among heavy smokers. The importance of quitting smoking should be emphasized in subjects with SCH who are heavy smokers.

Several reports suggested that thyroid hormone supplement might accelerate tumor growth or recurrence [58–59]. Hercbergs et al. suggested prudent consideration for thyroid hormone replacement when managing chemically hypothyroid patients with cancer [57]. To reduce heart failure and CVD mortality, the clinical practice guideline of American Thyroid Association recommends L-thyroxine treatment for patients with serum TSH levels exceeding 10 mIU/L and individualized consideration for SCH subjects with serum TSH less than 10 mIU/L [60]. Our analysis in this study revealed significantly higher cancer mortality in subjects with SCH than euthyroid. The impact of this observation deserves further investigation.

Our analysis demonstrated the association between SCH and risks of cancer mortality. Limitations of this study include: First, measurement of serum total T4 could be influenced by non-thyroidal conditions. We didn’t measure free T4 in our patients. However, measurement of total T4, instead of fT4, was also used in previous reports [8–9]. Second, without thyroid autoantibody data or thyroid sonography, the prevalence of autoimmune thyroid disorders in our participants was not clear. Third, the serum TSH and T4 levels and other laboratory data were checked when subjects were recruited. We did not have follow-up thyroid function data to confirm the persistence of SCH. The changes of other covariates during the follow-up period were not clear. Furthermore, the thyroxine regimen in SCH patients might potentially affect the risk, progression, or mortality of cancer. We did not know whether the SCH patients were treated by thyroxine or not. Fourth, thyroid dysfunction may have different influence on various cancers. Increasing cancer mortality may be caused by higher cancer incidence, later diagnosis, quality of care, aggressiveness of cancer, or poor response to therapy. Our data was not detailed enough to elucidate the cause of increasing cancer mortality in SCH. Fifth, as an observational study, possible residual confounding factors still remain even after adjustment with demographic, clinical, socioeconomic, and lifestyle factors as in our analysis.

Conclusions
We have found that SCH was independently associated with an increased risk for cancer mortality among adult Taiwanese.

Acknowledgments
We would like to thank Dr. Pei-Kun Sung at MJ Health Screening Center and subjects who participated in this study.

Author Contributions
Conceived and designed the experiments: FYT WYL KCH. Performed the experiments: WYL KCH. Analyzed the data: WYL CIL TCL CCL. Contributed reagents/materials/analysis tools: WYL KCH. Wrote the paper: FYT WYL KCH.

References
1. Borek C, Guernsey DL, Ong A, Edelman IS. Critical role played by thyroid hormone in induction of neoplastic transformation by chemical carcinogens in tissue culture. Proc Natl Acad Sci USA 1983; 80: 5749–5752. PMID: 6310591
2. Guernsey DL, Ong A, Borek C. Thyroid hormone modulation of X-ray induced in vitro neoplastic transformation. Nature (London) 1980; 288: 591–592. PMID: 7442803
3. Fatourechi V. Subclinical hypothyroidism: An update for primary care physicians. Mayo Clin Proc. 2009; 84(1): 65–71. doi: 10.1016/S0025-6196(11)60809-4 PMID: 19121255
4. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocrine Reviews 2008; 29(1): 76–131. PMID: 17991805

5. Imaizumi M, Akahoshi M, Ichimaru S, Nakashima E, Hida A, Soda M, et al. Risk for ischemic heart disease and all-cause mortality in subclinical hypothyroidism. J Clin Endocrinol Metab 2004; 89: 3365–3370. PMID: 15240616

6. Ochs N, Auer R, Bauer DC, Nanchen D, Gussukoo J, Cornuz J, et al. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med 2008; 148: 832–845. PMID: 18490668

7. Razvi S, Weaver JU, Vanderpump MP, Pearce SH. The incidence of ischemic heart disease and mortality in people with subclinical hypothyroidism: reanalysis of the Whickham Survey cohort. J Clin Endocrinol Metab 2010; 95: 1734–1740. doi: 10.1210/jc.2009-1749 PMID: 20150579

8. Rodondi N, den Ezen WP, Bauer DC, Cappola AR, Razvi S, Walsh JP, et al. Thyroid Studies Collaboration, Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA 2010; 304: 1365–1374. doi: 10.1001/jama.2010.1361 PMID: 20858880

9. Tseng FY, Lin WY, Lin CC, Lee LT, Li TC, Pi-Sunyer FX, et al. Body mass index and all-cause mortality in subclinical hypothyroidism. JAMA 2012; 307: 1133–1141. doi: 10.1001/jama.2012.3040 PMID: 22392154

10. Waring AC, Harrison S, Samuels MH, Ensrud KE, LeBlanc ES, Hoffman AR, et al. for the Osteoporotic Thvilum M, Brandt F, Brix TH, Hegedüs L. A review of the evidence for and against increased mortality.

11. Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, et al. The spectrum of thyroid disease in the United Kingdom: the Whickham Survey. Clin Endocrinol 1977; 7: 481–493. PMID: 5809014

12. Ministry of Health and Welfare, Taiwan. Statistics: Population Analysis. http://www.mohw.gov.tw/cht/DSOS/Statistic.aspx?f_list_no = 312&fod_list_no = 1856 accessed 2015 March 5.

13. Lin WY, Lee LT, Chen CY, Lo H, Hsia HH, Liu IL, et al. Optimal cut-off values for obesity: using simple anthropometric indices to predict cardiovascular risk factors in Taiwan. Int J Obes Relat Metab Disord. 2002; 26: 1232–1238. PMID: 12187401

14. Lin WY, Tsai SL, Albu JB, Lin CC, Li TC, Pi-Sunyer FX, et al. Body mass index and all-cause mortality in a large Chinese cohort. CMAJ 2011; 183: E329–336. doi: 10.1503/cmaj.101033 PMID: 21398246

15. Lin WY, Chiu TY, Lee LT, Lin CC, Huang CY, Huang KC. Betel nut chewing is associated with increased risk of cardiovascular disease and all-cause mortality in Taiwanese men. Am J Clin Nutr 2008; 87: 1204–1211. PMID: 18469240

16. Ghali WA, Quan H, Brant R, van Melle G, Caro JF, Faris PD, et al. APPROACH (Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease) Investigators. Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models. JAMA 2001; 286: 1494–1497. PMID: 11572743

17. Lee ET, Go OT. Survival analysis in public health research. Annu Rev Public Health 1997; 18: 105–134. PMID: 9143714

18. Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol 1977; 7: 481–493. PMID: 5809014

19. Canaris GJ, Manowitiz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med 2000; 160: 526–534. PMID: 10695693

20. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87: 489–499. PMID: 11836274

21. Razvi S, Weaver JU, Pearce SH. Subclinical thyroid disorders: significance and clinical impact. J Clin Pathol 2010; 63: 379–386. doi: 10.1136/jcp.2008.057414 PMID: 20418229

22. Chuang CC, Wang ST, Wang PW, Yu ML. Prevalence study of thyroid dysfunction in the elderly of Taiwan. Gerontology 1998; 44: 162–167. PMID: 9592689

23. Knudsen N, Laarup P, Rasmussen LB, Bølow I, Perrild H, Ovesen L, et al. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J Clin Endocrinol Metab 2005; 90: 4019–4024. PMID: 15970128

24. Iacobellis G, Ribaudo MC, Zappaterreno A, Iannucci CV, Leonetti F. Relationship of thyroid function with body mass index, leptin, insulin sensitivity and adiponectin in euthyroid obese women. Clin Endocrinol (Oxf) 2005; 62: 487–491. PMID: 15807981

25. Walsh JP, Bremner AP, Bursara MK, O'Leary P, Leedman PJ, Feddema P, et al. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med 2005; 165: 2467–2472. PMID: 16314542
26. Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 2006; 295: 1033–1041. PMID: 16507804

27. Garduño-Garcia Jde J, Alvirde-Garcia U, López-Carrasco G, Padilla Mendoza ME, Mehta R, Arellano-Campos O, et al. TSH and free thyroxine concentrations are associated with differing metabolic markers in euthyroid subjects. Eur J Endocrinol 2010; 163: 273–278. doi: 10.1530/EJE-10-0312 PMID: 20516204

28. Ashizawa K, Imaizumi M, Usa T, Tominaga T, Sera N, Hida A, et al. Metabolic cardiovascular disease risk factors and their clustering in subclinical hypothyroidism. Clin Endocrinol 2010; 72: 689–695. doi: 10.1111/j.1365-2265.2009.03697.x PMID: 20447067

29. Asvold BO, Vatten LJ, Nilsen TI, Bjoro T. The association between TSH within the reference range and serum lipid concentrations in a population-based study. The Hunt Study. Eur J Endocrinol 2007; 156: 181–186. PMID: 17287407

30. Igbal A, Jorde R, Figsenschau Y. Serum lipid levels in relation to serum thyrotropin-stimulating hormone and the effect of thyroxine treatment on serum lipid levels in subjects with subclinical hypothyroidism: the Tromsø Study. J Intern Med 2006; 260: 53–61. PMID: 16789979

31. Luboshitzky R, Aviv A, Herer P, Lavie L. Risk factors for cardiovascular disease in women with subclinical hypothyroidism. Thyroid 2002; 12: 421–425. PMID: 12097204

32. Nagasaki T, Inaba M, Kumeda Y, Hiura Y, Shirakawa K, Yamada S, et al. Increased pulse wave velocity in subclinical hypothyroidism. J Clin Endocrinol Metab 2006; 91: 154–158. PMID: 16234303

33. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. New Engl J Med 2003; 348: 1625–1638. PMID: 12711737

34. Basen-Engquist K, Chang M. Obesity and cancer risk: recent review and evidence. Current Oncology Reports. 2011; 13(1): 71–76. doi: 10.1007/s11912-010-0139-7 PMID: 21080117

35. Grossman E, Messerli FH, Boyko V, Goldburt U. Is there an association between hypertension and cancer mortality? Am J Med 2002; 112(6): 479–486. PMID: 11959059

36. Stocks T, Van Hemelrijck M, Manjer J, Bjoro T, Ulmer H, Hallmans, G, et al. Blood pressure and risk of cancer incidence and mortality in the Metabolic Syndrome and Cancer Project. Hypertension. 2012; 59: 802–810. doi: 10.1161/HYPERTENSIONAHA.111.189258 PMID: 22353615

37. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004; 159: 1160–1167. PMID: 15191933

38. Noto H, Tsujimoto T, Sasazuki T, Noda M. Significantly increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Endocr Pract. 2011; 17(4): 616–628. doi: 10.4158/EP10357.RA PMID: 21454235

39. Rywik SL, Manolio TA, Pajak A, Piotrowski W, Davis CE, Broda GB, et al. Association of lipids and lipoprotein level with total mortality and mortality caused by cardiovascular and cancer diseases (Poland and United States collaborative study on cardiovascular epidemiology). Am J Cardiol. 1999; 84(5): 540–548. PMID: 10482152

40. Perova NV, Oganov RG, Williams DH, Irving SH, Abernathy JR, Deev AD, et al. Association of high-density-lipoprotein cholesterol with mortality and other risk factors for major chronic noncommunicable diseases in samples of US and Russian men. Ann Epidemiol. 1995; 5(3): 179–185. PMID: 7606306

41. Pirie K, Peto R, Reeves G, Green J, Beral V. Million Women Study Collaborators. The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK. Lancet. 2013; 381(9861): 133–141. doi: 10.1016/S0140-6736(12)61720-6 PMID: 2310725

42. Inoue M, Nagata C, Tsuji I, Sugawara Y, Wakai K, Tamakoshi A, et al. Research Group for the Development and Evaluation of Cancer Prevention Strategies in Japan. Impact of alcohol intake on total mortality and mortality from major causes in Japan: a pooled analysis of six large-scale cohort studies. J Epidemiol Community Health 2012; 66: 448–456. doi: 10.1136/jech.2010.121830 PMID: 21148820

43. Trivedy CR, Craig G, Warnaekulasuriya S. The oral health consequences of chewing areca nut. Addict Biol 2002; 7: 115–125. PMID: 11900631

44. Hellevik AI, Asvold BO, Bjoro T, Romundstad PR, Nilsen TI, Vatten LJ. Thyroid function and cancer risk: a prospective population study. Cancer Epidemiol Biomarkers Prev 2009; 18: 570–574. doi: 10.1158/1055-9966.EPI-08-0911 PMID: 19155436

45. Loeser AA. A new therapy for prevention of post-operative recurrences in genital and breast cancer. A six-years study of prophylactic thyroid treatment. Br Med J. 1954; 2: 1380–1383. PMID: 13209124

46. Brinton LA, Hoffman DA, Hoover R, Fraumeni JF Jr. Relationship of thyroid disease and use of thyroid supplements to breast cancer risk. J Chronic Dis. 1984; 7(12): 877–893.
47. Cristofanilli M, Yamamura Y, Kau SW, Bevers T, Strom S, Patangan M, et al. Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer 2005; 103: 1122–1128. PMID: 15712375

48. Hoffman DA, McConahey WM, Brinton LA, Fraumeni JF Jr. Breast cancer in hypothyroid women using thyroid supplements. JAMA. 1984; 251(5): 616–619. PMID: 6690834

49. Kapdi CC, Wolfe JN. Breast cancer. Relationship to thyroid supplements for hypothyroidism. JAMA. 1976; 236: 1124–1127. PMID: 988872

50. Rosenberg AG, Dexeus F, Swanson DA, von Eschenbach AC. Relationship of thyroid disease to renal cell carcinoma: An epidemiologic study. Urology 1990; 35: 492–498. PMID: 2353376

51. Goldman MB, Monson RR, Maloof F. Cancer mortality in women with thyroid disease. Cancer Res 1990; 50: 2283–2289. PMID: 2317816

52. Hercbergs A, Leith JT. Spontaneous remission of metastatic lung cancer following myxedema coma: an apoptosis-related phenomenon? J Natl Cancer Inst 1993; 85: 1342–1343. PMID: 8393494

53. Metso S, Jaatinen P, Huhtala H, Auvinen A, Oksala H, Salmi J. Increased cardiovascular and cancer mortality after radiiodine treatment for hyperthyroidism. J Clin Endocrinol Metab 2007; 92: 2190–2196. PMID: 17374710

54. Schmidinger M, Vogl UM, Bojic M, Lamm W, Heinzl H, Haitel A, et al. Hypothyroidism in patients with renal cell carcinoma. Blessing or curse? Cancer 2011; 117: 534–544. doi: 10.1002/cncr.25422 PMID: 20845482

55. Riesenbeck LM, Bierer S, Hoffmeister I, Köpke T, Papavassilis P, Hertle L, et al. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World J Urol 2011; 29: 807–813. doi: 10.1007/s00345-010-0627-2 PMID: 21153827

56. Nelson M, Hercbergs A, Rybicki L, Strome M. Association between development of hypothyroidism and improved survival in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2006; 132: 1041–1046. PMID: 17043248

57. Hercbergs AH, Ashur-Fabian O, Garfield D. Thyroid hormones and cancer: clinical studies of hypothyroidism in oncology. Curr Endocrinol Diabetes Obes 2011; 17: 432–436.

58. Hercbergs A. The thyroid gland as an intrinsic biologic response-modifier in advanced neoplasia—a novel paradigm. In Vivo. 1996; 10(2): 245–247. PMID: 8744809

59. Hercbergs A. Spontaneous remission of cancer—a thyroid hormone dependent phenomenon? Anti-cancer Res. 1999; 19(6A): 4839–4844. PMID: 10697597

60. Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, et al. American Association Of Clinical Endocrinologists And American Thyroid Association Taskforce On Hypothyroidism In Adults. Clinical Practice Guidelines for Hypothyroidism in Adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid 2012; 22(12): 1200–1235. doi: 10.1089/thy.2012.0205 PMID: 22954017